Carregant...
An Adaptive, Phase II, Dose-Finding Clinical Trial Design to Evaluate l-Carnitine in the Treatment of Septic Shock Based on Efficacy and Predictive Probability of Subsequent Phase III Success
OBJECTIVES: Sepsis is the tenth leading cause of death in the United States. Despite extensive research, mortality rates for sepsis have not substantially improved in the last several decades. We describe an innovative phase II clinical trial design for evaluating the addition of l-carnitine to the...
Guardat en:
| Publicat a: | Crit Care Med |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4334380/ https://ncbi.nlm.nih.gov/pubmed/23514753 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCM.0b013e318287f850 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|